OncoPatch provides a disposable low‑energy beta brachytherapy patch that delivers targeted radiation to basal and squamous cell skin cancers in a single office visit. The shallow penetration protects surrounding tissue, eliminating the need for surgical excision, reconstruction, and specialized radiation facilities, allowing dermatology and primary‑care clinics to treat lesions efficiently and with minimal scarring.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with basal cell carcinoma or squamous cell carcinoma often require surgical excision, which can lead to scarring, need for reconstruction, and multiple clinic visits, especially for lesions in cosmetically sensitive areas or for individuals who are poor surgical candidates.
Solution
OncoPatch delivers low‑energy beta brachytherapy directly to the skin lesion in a physician’s office. The shallow penetration of beta particles confines the radiation dose to the tumor while sparing surrounding healthy tissue, reducing side effects and eliminating the need for surgical reconstruction. Treatment can be completed in a single office visit, improving patient convenience and allowing clinics to increase throughput without additional capital equipment or specialized staff. The non‑invasive approach is suited for cosmetically sensitive sites and for patients who cannot undergo surgery.
Target Audience
Primary customers are dermatologists, dermatologic surgeons, and primary‑care physicians who treat basal and squamous cell skin cancers, particularly in cosmetically sensitive areas or in patients unsuitable for surgery.
Features
- Disposable patch that conforms to the lesion and emits low‑energy beta particles for targeted radiation
- Shallow penetration depth that protects deeper tissues and preserves surrounding skin
- Single‑application protocol often completed in one office visit
- No requirement for surgical facilities, reconstruction, or specialized radiation suites
- Compatible with existing clinical workflows; no capital investment or additional personnel needed
- Favorable safety profile demonstrated in published brachytherapy literature for non‑melanoma skin cancer